Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes

BioFactors ◽  
2021 ◽  
Author(s):  
Shabnam Radbakhsh ◽  
George E. Barreto ◽  
Abigail R. Bland ◽  
Amirhossein Sahebkar
Keyword(s):  
Type 2 Diabetes ◽  
Neurodegenerative Diseases ◽  
Small Molecule ◽  
Amyloid Aggregation

Differential effects of silver and iron oxide nanoparticles on IAPP amyloid aggregation

2017 ◽  
Vol 5 (3) ◽  
pp. 485-493 ◽  
Author(s):  
Miaoyi Wang ◽  
Aleksandr Kakinen ◽  
Emily H. Pilkington ◽  
Thomas P. Davis ◽  
Pu Chun Ke
Keyword(s):  
Type 2 Diabetes ◽  
Iron Oxide ◽  
Neurodegenerative Diseases ◽  
Protein Aggregation ◽  
Small Molecules ◽  
Iron Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Amyloid Aggregation ◽  
Differential Effects

Recent studies have shown promise on the use of small molecules and nanoparticles (NPs) for the inhibition of protein aggregation, a hallmark of neurodegenerative diseases and type 2 diabetes (T2D).

scholarly journals Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes

RSC Advances ◽  
2020 ◽  
Vol 10 (21) ◽  
pp. 12166-12182
Author(s):  
Anchala Kumari ◽  
Pallavi Somvanshi ◽  
Abhinav Grover
Keyword(s):  
Alzheimer’S Disease ◽  
Type 2 Diabetes ◽  
Alzheimer's Disease ◽  
Metabolic Disorders ◽  
Misfolded Proteins ◽  
Amyloid Aggregation ◽  
Large Numbers

Large numbers of neurological and metabolic disorders occurring in humans are induced by the aberrant growth of aggregated or misfolded proteins.

scholarly journals Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity

2015 ◽  
Vol 39 (5) ◽  
pp. 363 ◽  
Author(s):  
Miki Okada-Iwabu ◽  
Masato Iwabu ◽  
Kohjiro Ueki ◽  
Toshimasa Yamauchi ◽  
Takashi Kadowaki
Keyword(s):  
Type 2 Diabetes ◽  
Small Molecule ◽  
Short Life

scholarly journals Small molecule SWELL1-LRRC8 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes

2021 ◽  
Author(s):  
Susheel K. Gunasekar ◽  
Litao Xie ◽  
Pratik R. Chheda ◽  
Chen Kang ◽  
David M. Kern ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Liver Disease ◽  
Insulin Sensitivity ◽  
Glycemic Control ◽  
Small Molecule ◽  
Fatty Liver Disease ◽  
Β Cell ◽  
Nonalcoholic Fatty Liver

AbstractType 2 diabetes (T2D) is associated with insulin resistance, impaired insulin secretion from the pancreatic β-cell, and nonalcoholic fatty liver disease (NAFLD). SWELL1 (LRRC8a) ablation impairs adipose and skeletal muscle insulin-pAKT2 signaling, β-cell insulin secretion and glycemic control - suggesting that SWELL1-LRRC8 complex dysfunction contributes to T2D pathogenesis. Here, we show that ICl,SWELL and SWELL1 protein are reduced in adipose and β-cells in murine and human T2D. Combining cryo-electron microscopy, molecular docking, medicinal chemistry, and functional studies, we define a structure activity relationship to rationally-designed active derivatives (SN-40X) of a SWELL1 channel inhibitor (DCPIB/SN-401), that bind the SWELL1-LRRC8 hexameric complex, restore SWELL1-LRRC8 protein, plasma membrane trafficking, signaling and islet insulin secretion via SWELL1-dependent mechanisms. In vivo, SN-401 and active SN-40X compounds restore glycemic control and prevents NAFLD by improving insulin-sensitivity and insulin secretion in murine T2D. These findings demonstrate that small molecule SWELL1 modulators restore SWELL1-dependent insulin-sensitivity and insulin secretion in T2D and may represent a first-in-class therapeutic approach for T2D and NAFLD.

Sign in / Sign up

Export Citation Format

Share Document